Journal of Internal Medicine最新文献

{"title":"Predictors of remission and relapse in retroperitoneal fibrosis.","authors":"Milena Bond, Alessandra Bettiol, Eugenia Accorsi Buttini, Giorgio Trivioli, Giulia Palazzini, Ilaria Fibbi, Michelangelo Tesi, Edoardo Biancalana, Christian Dejaco, Giacomo Emmi, Augusto Vaglio","doi":"10.1111/joim.70017","DOIUrl":"https://doi.org/10.1111/joim.70017","url":null,"abstract":"<p><strong>Objectives: </strong>In retroperitoneal fibrosis (RPF), glucocorticoids (GC), alone or in combination with immunosuppressive agents, induce remission in 80%-90% of patients but up to two thirds of them relapse. There is limited knowledge on outcome predictors in RPF. We aimed to identify clinical, laboratory and imaging predictors of remission and relapse in RPF.</p><p><strong>Methods: </strong>We included consecutive RPF patients treated with 6-9-month courses of GC with/without immunosuppressive agents. Baseline and post-treatment computed tomography, magnetic resonance imaging and ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET) were assessed. The potential predictive value of the examined parameters as predictors of remission and time-to-relapse was analysed using logistic and Cox regression models.</p><p><strong>Results: </strong>Of 152 patients screened, 115 were included. Of them, 101 (87.8%) achieved remission a median of 4 months (interquartile range 3-5) after starting treatment. At multivariable analysis, smoking (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.11-0.99) and atypical RPF localization (e.g., pelvic) (OR 0.11, 95% CI 0.02-0.52) were negatively associated with remission, whereas pre-treatment ¹⁸F-FDG-PET activity was positively associated (OR 11.51, 95% CI 1.35-98.20). A median of 33 months (17-57) after treatment initiation, 42% patients relapsed (median time from remission to relapse, 14 months [8-26]). Thoracic vessel involvement and positive ¹⁸F-FDG-PET at the end of treatment independently predicted relapse (hazard ratio [HR] 2.61, 95% CI 1.19-5.68 and HR 3.47, 95% CI 1.54-7.82, respectively).</p><p><strong>Conclusions: </strong>Metabolic activity of RPF at ¹⁸F-FDG-PET is an important predictor of remission and relapse. Smoking and atypical localization are negatively associated with remission, whereas thoracic aorta involvement is associated with relapse risk.</p>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal insights into the natural history of Type 2 diabetes among Koreans: A 20-year community-based prospective cohort study","authors":"Wonsuk Choi,&nbsp;Joon Ho Moon,&nbsp;Hun Jee Choe,&nbsp;Howard H. Chang,&nbsp;Dimple Kondal,&nbsp;K. M. Venkat Narayan,&nbsp;Nam H. Cho","doi":"10.1111/joim.70010","DOIUrl":"10.1111/joim.70010","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate the natural history of diabetes mellitus (DM) based on metabolic phenotypes of prediabetes in a community-based prospective study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Individuals aged 40–69 years without DM were followed for 20 years. Glycemic parameters, including the 75 g oral glucose tolerance test, were assessed at baseline and biennially thereafter. Markov models were used to estimate each glycemic state's annual transition probabilities and average total length of residence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 7,676 participants without DM, 205 had isolated impaired fasting glucose (iIFG), and 1,753 had impaired glucose tolerance (IGT) at baseline. During the 17.5 years of follow-up, 2,313 (30.1%) cases of DM occurred. The annual transition to DM for those with iIFG was 7.7% (95% confidence interval [CI] 6.9, 8.5) and 6.9% (95% CI 6.6, 7.3) for those with IGT. In the normoglycemia ↔ iIFG → DM model, the total length in normoglycemia was 49.4 years (95% CI 47.0, 52.1), and the length in iIFG was 6.3 years (95% CI 5.9, 6.8). In the normoglycemia ↔ IGT → DM model, the total length in normoglycemia was 34.0 years (95% CI 32.4, 35.4), and the length in IGT was 11.9 years (95% CI 11.1, 12.5).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Individuals remained normoglycemic for long periods. However, the progression to DM occurs rapidly once prediabetes develops, regardless of the metabolic phenotype.</p>\u0000 </section>\u0000 </div>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 4","pages":"336-348"},"PeriodicalIF":9.2,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.70010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine and the risk of major adverse cardiovascular events in patients with gout and Type 2 diabetes: A nationwide cohort study.","authors":"Minjeong Jeon, Yongtai Cho, Sungho Bea, Wonkyoung You, Sung Kweon Cho, Seungho Ryu, Yoosoo Chang, Ju-Young Shin","doi":"10.1111/joim.70012","DOIUrl":"https://doi.org/10.1111/joim.70012","url":null,"abstract":"<p><strong>Background: </strong>Type 2 diabetes mellitus (T2DM) and gout are associated with an increased risk of cardiovascular events. Despite the approval for the secondary prevention of cardiovascular diseases by the United States Food and Drug Administration in 2023, evidence regarding the effectiveness of colchicine among T2DM population remains limited.</p><p><strong>Objectives: </strong>We aimed to evaluate the association between the use of colchicine and the risk of major adverse cardiovascular events (MACE) among patients with gout and T2DM.</p><p><strong>Methods: </strong>We conducted a nationwide, population-based cohort study with active comparator, new-user design using nationwide claims data of South Korea (2010-2022). Patients with T2DM and gout who initiated colchicine or non-steroidal anti-inflammatory drugs (NSAIDs) from 2011 to 2022 were included. The primary outcome was MACE (myocardial infarction, ischemic stroke, and cardiovascular death). Secondary outcomes were each individual components of primary outcome and hospitalization due to heart failure. As-treated approach with 30-day grace period was applied.</p><p><strong>Results: </strong>Before propensity score (PS) matching, 13,019 colchicine users and 111,594 NSAIDs users were included in the study cohort (mean age, 65.5 vs. 62.9; 35.0% vs. 29.8% female). After 1:2 PS matching, 12,908 colchicine users and 25,816 NSAIDs users remained (mean age, 65.7 vs. 65.7 years; 35.2% vs. 35.1% female). The PS-matched hazard ratio for MACE was 0.94 (95% confidence interval 0.65-1.36), and all secondary outcomes also resulted in null findings.</p><p><strong>Conclusions: </strong>Use of colchicine does not significantly reduce the risk of MACE compared with NSAIDs in a real-world population with T2DM and gout in South Korea between 2011 and 2022.</p>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inter-organ crosstalk: The kidney's role in systemic health and disease.","authors":"Carmine Zoccali, Rajiv Agarwal, Francesca Mallamaci, Kitty J Jager, Vianda Stel, Mehmet Kanbay, Carol Pollock, Kamyar Kalantar-Zadeh, Claudio Ronco, Raymond Vanholder","doi":"10.1111/joim.70015","DOIUrl":"https://doi.org/10.1111/joim.70015","url":null,"abstract":"<p><p>This review elucidates the critical role of inter-organ crosstalk in systemic health, focusing on the kidney's interactions with the heart, bone marrow, lung, liver, intestine, bone-vascular, and nervous system. These interactions are vital for maintaining physiological homeostasis and are mediated by hormones, cytokines, and metabolites. The kidney's role in these networks is pivotal, as dysfunction can exacerbate systemic diseases, highlighting the need for integrated therapeutic strategies. Chronic kidney disease and acute kidney injury serve as key examples of how kidney dysfunction impacts other organs, leading to complex disease states. The central idea is that the kidney functions within a network of physiological processes, influencing and being influenced by other organs. This review provides an overview of the mechanisms underlying kidney-related inter-organ communication, emphasizing the significance of these interactions in disease progression. We explore how advanced computational models and multi-omics approaches can enhance our understanding of these complex networks, paving the way for precision medicine. The insights derived from this work underscore the potential for future research in developing innovative treatments that target these intricate pathways. By fostering interdisciplinary collaboration and leveraging emerging technologies, we aim to address the multifaceted nature of systemic diseases, offering new avenues for therapeutic intervention. This review represents a paradigm shift from reductionist to integrative approaches, emphasizing the importance of systemic balance and adaptation in human health, and sets the stage for future exploration into the interconnectedness of body systems.</p>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regarding: Standard and advanced echocardiographic study of patients with Paget's disease of bone: Evidence of a pagetic heart disease?","authors":"Huihui Wu, Lihong Wang, Dong Wang","doi":"10.1111/joim.70014","DOIUrl":"https://doi.org/10.1111/joim.70014","url":null,"abstract":"","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144843888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Effects of SGLT2 inhibitors on transplant survival and key clinical outcomes in heart transplant recipients with diabetes”","authors":"","doi":"10.1111/joim.70009","DOIUrl":"10.1111/joim.70009","url":null,"abstract":"<p>Yen FS, Hung YM, Huang JY, Hsu CC, Cheng WY, Hwu CM, et al. Effects of SGLT2 inhibitors on transplant survival and key clinical outcomes in heart transplant recipients with diabetes. J Intern Med. 2025;297(5):532-542. https://doi.org/10.1111/joim.20077</p><p>In the originally published article, the affiliation for Jing-Yang Huang was incorrectly listed.</p><p>The incorrect affiliation was:</p><p>“6 Institute of Medicine, Chung Shan Medical University, Taichung City, Taiwan”</p><p>The correct affiliations for Jing-Yang Huang are:</p><p>“6 Institute of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan; Department of Medical Research, Chung Shan Medical University Hospital, Taichung, 402, Taiwan.”</p><p>We apologize for this error.</p>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 4","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.70009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144843887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatments","authors":"Martin Jädersten,&nbsp;Ingrid Lilienthal,&nbsp;Christer Nilsson,&nbsp;Louisa Fredrikson,&nbsp;Cornelis Jan Pronk,&nbsp;Kristian Løvvik Juul-Dam,&nbsp;Mika Kontro,&nbsp;Nikolas Herold","doi":"10.1111/joim.70004","DOIUrl":"10.1111/joim.70004","url":null,"abstract":"<p>Although outcomes for newly diagnosed acute myeloid leukaemia (AML) have been incrementally improved over the last decades, management of relapsed and refractory (R/R) AML remains a medical challenge. A curative intent for R/R AML usually involves chemotherapy (with or without targeted therapy) with subsequent consolidation, including allogeneic haematopoietic stem cell transplantation. Despite this, long-term survival rates of R/R AML only reach approximately 10% in adults and 40% in children. Given this great unmet clinical need, this review outlines the current and emerging paradigms for preventing and treating R/R AML. Somatic mutations, gene expression, and functional drug testing are important for the selection of small molecule inhibitors of oncogenic signalling pathways (e.g., FLT3), menin inhibitors that disrupt leukemogenic programmes, inhibitors of isocitrate dehydrogenases to restore oncometabolic homoeostasis, and proapoptotic Bcl-2 homology 3 (BH3) mimetics, such as venetoclax. Targeting the recently identified resistance factor SAMHD1 promises to overcome resistance to cytarabine and fludarabine. Given the growing number of potential combinatorial drug regimens and the genetic heterogeneity of AML, real-time <i>ex vivo</i> drug response profiling to guide individualized treatment decisions will become an important complement. We argue that better outcomes for R/R AML critically depend on being guided by precision oncology to define the best combination of chemotherapy, targeted therapy, and immunological therapy informed by phenotypic and genotypic patient- and disease-specific parameters.</p>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 4","pages":"297-318"},"PeriodicalIF":9.2,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.70004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144797753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regarding: Standard and advanced echocardiographic study of patients with Paget's disease of bone: Evidence of a Pagetic heart disease?","authors":"Giuseppe Famularo","doi":"10.1111/joim.70011","DOIUrl":"https://doi.org/10.1111/joim.70011","url":null,"abstract":"","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":9.2,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital-treated infections and the risk and prognosis of amyotrophic lateral sclerosis: A population-based study","authors":"Yihan Hu,&nbsp;Charilaos Chourpiliadis,&nbsp;Caroline Ingre,&nbsp;Viktor H. Ahlqvist,&nbsp;Jiangwei Sun,&nbsp;Huan Song,&nbsp;Yudi Pawitan,&nbsp;Fredrik Piehl,&nbsp;Fang Fang","doi":"10.1111/joim.70008","DOIUrl":"10.1111/joim.70008","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Infection has been suspected as a risk factor for amyotrophic lateral sclerosis (ALS). However, previous research has focused on specific pathogens and rarely examined the influence of infection on disease progression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To assess whether hospital-treated infections correlate with the risk and prognosis of ALS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using data from the Swedish Motor Neuron Disease Quality Registry, we conducted three nested case-control studies, including 1159 individuals diagnosed with ALS during 2015–2023 and 5795 age- and sex-matched population controls, 1558 full-sibling controls, and 680 spouse controls, respectively. We used conditional logistic regression to estimate the association of hospital-treated infections with subsequent risk of ALS and Cox model to assess the association of pre- or post-diagnostic infections with mortality after an ALS diagnosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Hospital-treated infections before diagnosis were associated with an increased risk of ALS in the population comparison (odds ratio [OR] 1.31; 95% confidence interval [CI] 1.15–1.49). A similar association was noted after excluding infections within 3-, 5-, or 10-years preceding ALS diagnosis and was confirmed in sibling and spouse comparisons, although results were not always statistically significant. Patients with a hospital-treated infection before diagnosis were more likely to present with bulbar symptoms, poorer functional status, and higher prevalence of anxiety and depressive symptoms at diagnosis than others. Pre-diagnostic infections were not associated with mortality, whereas post-diagnostic infections were associated with increased mortality (hazard ratio [HR] 1.89; 95%CI 1.59–2.24) among ALS patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Hospital-treated infections are associated with an increased risk of ALS and may modify its clinical presentation at diagnosis. Post-diagnostic infections are associated with poor survival in ALS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 4","pages":"349-360"},"PeriodicalIF":9.2,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.70008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144787921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Choosing oral antihyperglycaemic drugs in people living with Type 2 diabetes and severe chronic kidney disease","authors":"Mikael Rydén","doi":"10.1111/joim.70002","DOIUrl":"10.1111/joim.70002","url":null,"abstract":"&lt;p&gt;Managing hyperglycaemia in individuals with Type 2 diabetes (T2D) and advanced chronic kidney disease (CKD) involves several important considerations [&lt;span&gt;1&lt;/span&gt;]. For instance, metformin is renally excreted, and a reduced estimated glomerular filtration rate (eGFR) increases the risk of drug accumulation, potentially leading to serious adverse events such as lactic acidosis. Although sulphonylureas and pioglitazone are primarily metabolized in the liver, their active metabolites are renally excreted, which—particularly in the context of impaired kidney function—may increase the risk of hypoglycaemia or fluid retention, respectively. SGLT2 inhibitors have limited glucose-lowering efficacy in patients with eGFR values below 20–25 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;. Additionally, GLP-1 receptor agonists promote weight loss, which may be undesirable in normal-weight patients, and insulin therapy, though often necessary, is associated with a heightened risk of hypoglycaemia and can be challenging to optimize in this vulnerable group. In contrast, the meglitinide repaglinide has been considered a particularly suitable oral agent under these circumstances. It undergoes hepatic metabolism, and only its inactive metabolites are excreted renally. Moreover, repaglinide's short duration of action and meal-time dosing provide safety and additional flexibility in glucose control.&lt;/p&gt;&lt;p&gt;Dipeptidyl peptidase-4 inhibitors (DPP-4i), such as sitagliptin and linagliptin, have been in clinical use for nearly two decades and are generally regarded as safe, with a favourable side-effect profile. Notably, their risk of inducing hypoglycaemia is significantly lower compared to sulphonylureas and meglitinides. This is attributed to their glucose-dependent mechanism of action, with insulinotropic effects markedly reduced at plasma glucose concentrations below approximately 4.5 mmol/L. Furthermore, DPP-4i are weight-neutral, which may be advantageous for patients with T2D and CKD in the normal or lower body mass index range. The pharmacokinetics of agents within this class vary. Thus, while sitagliptin is primarily excreted unchanged by the kidneys, linagliptin undergoes hepatic metabolism [&lt;span&gt;2&lt;/span&gt;]. Consequently, although sitagliptin requires dose adjustment in the context of reduced eGFR, linagliptin does not. Importantly, sitagliptin itself is not considered intrinsically nephrotoxic, even in the setting of advanced CKD. However, despite these favourable characteristics, clinical evidence on the safety and efficacy of DPP-4i in patients with T2D and Stage 5 CKD (eGFR &lt;15 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;) remains limited.&lt;/p&gt;&lt;p&gt;It is therefore timely to highlight the work by Hung et al., ‘Use of dipeptidyl peptidase-4 inhibitors is associated with lower risk of severe renal outcomes in pre-dialysis patients with Type 2 diabetes: A cohort study’ in the Journal of Internal Medicine [&lt;span&gt;3&lt;/span&gt;]. In this study, the authors investigated renal outcomes in adults with T2D","PeriodicalId":196,"journal":{"name":"Journal of Internal Medicine","volume":"298 3","pages":"149-151"},"PeriodicalIF":9.2,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/joim.70002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}